IND Swift Laboratories Ltd
INDSWFTLABIND Swift Laboratories Ltd
INDSWFTLABPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
LowUndervalued compared to the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
1.57 | 0.63 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.90 | 6.61 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Ind-Swift Laboratories Limited is a company focused on the development of active pharmaceutical ingredients (APIs).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 667.85 | 737.46 | 784.01 | 876.44 | 813.04 | 914.04 | 1,082.23 | 1,240.81 | 1,712.86 | 1,169.08 | ||||||||||
Raw Materials | 352.08 | 377.52 | 374.40 | 421.46 | 409.10 | 457.35 | 581.87 | 673.70 | 628.51 | 619.29 | ||||||||||
Power & Fuel Cost | 22.65 | 26.75 | 30.70 | 39.15 | 36.40 | 38.84 | 60.27 | 77.84 | 63.51 | |||||||||||
Employee Cost | 66.85 | 69.65 | 88.12 | 97.63 | 102.72 | 106.55 | 127.09 | 135.84 | 152.81 | |||||||||||
Selling & Administrative Expenses | 55.36 | 63.19 | 81.21 | 62.10 | 74.89 | 79.16 | 62.80 | 63.65 | 80.66 | |||||||||||
Operating & Other expenses | 62.52 | 79.02 | 58.78 | 10.18 | 12.15 | 26.62 | 11.08 | 53.73 | 101.20 | |||||||||||
EBITDA | 108.39 | 121.33 | 150.80 | 245.92 | 177.78 | 205.52 | 239.12 | 236.05 | 686.17 | 549.79 | ||||||||||
Depreciation/Amortization | 84.75 | 88.26 | 86.62 | 104.05 | 90.06 | 87.29 | 131.04 | 57.36 | 53.30 | 26.70 | ||||||||||
PBIT | 23.64 | 33.07 | 64.18 | 141.87 | 87.72 | 118.23 | 108.08 | 178.69 | 632.87 | 523.09 | ||||||||||
Interest & Other Items | 106.42 | 88.37 | 28.21 | 92.20 | 107.49 | 100.22 | 95.55 | 92.17 | 51.10 | 10.16 | ||||||||||
PBT | -82.78 | -55.30 | 35.97 | 49.67 | -19.77 | 18.01 | 12.53 | 86.52 | 581.77 | 512.93 | ||||||||||
Taxes & Other Items | -24.10 | -16.16 | 14.01 | 20.73 | 1.42 | 21.16 | 14.68 | 38.92 | 160.80 | 139.51 | ||||||||||
Net Income | -58.68 | -39.14 | 21.96 | 28.94 | -21.19 | -3.15 | -2.15 | 47.60 | 420.97 | 373.42 | ||||||||||
EPS | -14.33 | -9.12 | 4.86 | 6.21 | -3.96 | -0.53 | -0.36 | 8.03 | 71.14 | 63.20 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
IND Swift Laboratories Ltd | 1.39 | 0.63 | — |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 29.41 | 4.52 | 0.87% |
Torrent Pharmaceuticals Ltd | 68.50 | 16.55 | 0.84% |
Price Comparison
Compare INDSWFTLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Aug 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
INDSWFTLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 20, 2011
Dividend/Share
₹1.00
Ex DateEx Date
Sep 20, 2011
Cash Dividend
Ex DateEx DateSep 16, 2010
Dividend/Share
₹1.00
Ex DateEx Date
Sep 16, 2010
Net profit of Ind-Swift Laboratories declined 98.70% to Rs 0.41 crore in the quarter ended September 2024 as against Rs 31.66 crore during the previous quarter ended September 2023. Sales declined 95.87% to Rs 11.96 crore in the quarter ended September 2024 as against Rs 289.71 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales11.96289.71 -96 OPM %-98.6622.67 - PBDT0.8051.95 -98 PBT0.5838.77 -99 NP0.4131.66 -99 Powered by Capital Market - Live
Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2024.Powered by Capital Market - Live
Ind-Swift Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Net profit of Ind-Swift Laboratories declined 94.55% to Rs 0.94 crore in the quarter ended June 2024 as against Rs 17.24 crore during the previous quarter ended June 2023. Sales declined 89.31% to Rs 33.17 crore in the quarter ended June 2024 as against Rs 310.34 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.17310.34 -89 OPM %-29.3619.43 - PBDT1.2345.52 -97 PBT0.9831.64 -97 NP0.9417.24 -95 Powered by Capital Market - Live
Net profit of Ind-Swift Laboratories declined 63.70% to Rs 6.19 crore in the quarter ended June 2024 as against Rs 17.05 crore during the previous quarter ended June 2023. Sales declined 89.81% to Rs 30.46 crore in the quarter ended June 2024 as against Rs 299.01 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales30.46299.01 -90 OPM %-14.8720.01 - PBDT6.4444.99 -86 PBT6.1931.10 -80 NP6.1917.05 -64 Powered by Capital Market - Live
Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Why shares of PI Industries are down 8% today? Good time to buy?
PI Industries decline after terminating business transfer agreement with Ind Swift
PI Industries: A Sizeable Entry Into Pharma
PI Industries to acquire Ind Swift’s API biz for Rs 1,530 cr
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 14.34%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.4% to 0.45%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 70.82%, vs industry avg of 15.27%